LG100754

Cat. No.: HY-108523

CAS No.: 180713-37-5

Molecular Formula: $C_{26}H_{36}O_3$

Molecular Weight: 396.56

Target: RAR/RXR

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (252.17 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5217 mL	12.6084 mL	25.2169 mL
	5 mM	0.5043 mL	2.5217 mL	5.0434 mL
	10 mM	0.2522 mL	1.2608 mL	2.5217 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 2.5 mg/mL (6.30 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR[1].

IC_{50} & Target	PPARα	PPARγ

In Vitro

LG100754 is a selective activator of endogenous RXR heterodimers[1].
LG100754 can also improve TNFα-mediated insulin resistance in mature adipocytes[1].
LG100754 acts as a bona fide activator of endogenous RXR:PPARγ heterodimers and regulator of insulin-dependent signaling pathways[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LG100754 (100 mg/kg) completely blocks the increase in glucose levels, suggesting that LG100754 can improve insulin resistance in vivo[1].

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Cesario RM, et al. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA